Profile data is unavailable for this security.
About the company
Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.
- Revenue in USD (TTM)84.82m
- Net income in USD-21.43m
- Incorporated2015
- Employees100.00
- LocationY-mAbs Therapeutics Inc230 PARK AVENUE, SUITE 3350NEW YORK 10169United StatesUSA
- Phone+1 (212) 847-9841
- Fax+1 (302) 655-5049
- Websitehttps://www.ymabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
SIGA Technologies Inc | 139.92m | 68.07m | 615.65m | 45.00 | 9.21 | 3.13 | 8.96 | 4.40 | 0.9399 | 0.9399 | 1.95 | 2.77 | 0.6227 | 0.3329 | 4.21 | 3,109,272.00 | 30.29 | 22.34 | 36.42 | 27.56 | 87.69 | 88.65 | 48.65 | 41.14 | 3.23 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
ProKidney Corp | 0.00 | -35.47m | 621.52m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
Hillevax Inc | 0.00 | -123.57m | 625.24m | 90.00 | -- | 2.26 | -- | -- | -3.04 | -3.04 | 0.00 | 5.57 | 0.00 | -- | -- | 0.00 | -37.35 | -- | -39.90 | -- | -- | -- | -- | -- | -- | -- | 0.0868 | -- | -- | -- | 22.68 | -- | -- | -- |
Cogent Biosciences Inc | 0.00 | -192.41m | 625.31m | 164.00 | -- | 2.85 | -- | -- | -2.40 | -2.40 | 0.00 | 2.99 | 0.00 | -- | -- | 0.00 | -62.65 | -49.53 | -70.07 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Dianthus Therapeutics Inc | 2.83m | -43.56m | 625.71m | 53.00 | -- | 1.87 | -- | 221.41 | -10.77 | -10.77 | 0.4429 | 11.40 | 0.0173 | -- | -- | 53,320.75 | -26.72 | -41.40 | -28.86 | -44.70 | -- | -- | -1,541.22 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Sinovac Biotech Ltd | 420.88m | -359.71m | 639.90m | 3.56k | -- | -- | -- | 1.52 | -3.63 | -3.63 | 3.94 | 87.08 | 0.0292 | 2.75 | 0.6035 | 118,289.80 | -5.09 | 55.60 | -7.77 | 93.17 | -46.96 | 91.39 | -174.00 | 67.88 | 9.74 | -- | 0.0174 | -- | -92.30 | 53.64 | -98.73 | 33.12 | 102.27 | -- |
enGene Holdings Inc | 0.00 | -106.80m | 650.49m | 33.00 | -- | 5.48 | -- | -- | -4.60 | -4.60 | 0.00 | 2.69 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1.37 | 0.2653 | -- | -- | -- | -260.87 | -- | -- | -- |
Nuvation Bio Inc | 0.00 | -75.80m | 656.20m | 51.00 | -- | 0.9629 | -- | -- | -0.3463 | -0.3463 | 0.00 | 2.76 | 0.00 | -- | -- | 0.00 | -11.72 | -16.27 | -11.97 | -16.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.25 | -- | -- | -- |
Y-mAbs Therapeutics Inc | 84.82m | -21.43m | 669.35m | 100.00 | -- | 6.61 | -- | 7.89 | -0.4909 | -0.4909 | 1.94 | 2.31 | 0.6299 | 1.93 | 4.85 | 848,190.00 | -15.91 | -44.23 | -19.40 | -50.45 | 86.60 | -- | -25.26 | -181.13 | 5.27 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
Disc Medicine Inc | 0.00 | -76.43m | 673.79m | 74.00 | -- | 1.93 | -- | -- | -3.49 | -3.49 | 0.00 | 14.17 | 0.00 | -- | -- | 0.00 | -26.90 | -- | -29.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Ocular Therapeutix Inc | 58.44m | -80.74m | 690.37m | 267.00 | -- | 5.86 | -- | 11.81 | -0.9939 | -0.9939 | 0.7233 | 0.7927 | 0.2912 | 2.47 | 2.46 | 218,883.90 | -40.23 | -46.70 | -48.19 | -54.18 | 90.96 | 89.36 | -138.15 | -228.65 | 6.59 | -6.57 | 0.4512 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
Evolus Inc | 202.09m | -61.69m | 705.81m | 273.00 | -- | -- | -- | 3.49 | -1.08 | -1.08 | 3.55 | -0.3578 | 1.10 | 4.12 | 7.63 | 740,238.10 | -33.62 | -40.92 | -45.33 | -59.74 | 69.54 | 65.43 | -30.52 | -80.46 | 2.10 | -3.47 | 1.21 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
Longboard Pharmaceuticals Inc | 0.00 | -54.42m | 711.56m | 50.00 | -- | 11.83 | -- | -- | -2.39 | -2.39 | 0.00 | 1.67 | 0.00 | -- | -- | 0.00 | -89.72 | -- | -105.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Pliant Therapeutics Inc | 1.58m | -161.34m | 716.85m | 158.00 | -- | 1.51 | -- | 453.70 | -2.75 | -2.75 | 0.0269 | 7.90 | 0.0037 | -- | 1.59 | 10,000.00 | -37.40 | -33.24 | -39.82 | -35.39 | -- | -- | -10,211.14 | -360.29 | -- | -- | 0.0208 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
Holder | Shares | % Held |
---|---|---|
HBM Partners AG (Investment Management)as of 31 Dec 2023 | 3.30m | 7.53% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 2.59m | 5.92% |
Paradigm BioCapital Advisors LPas of 27 Mar 2024 | 2.20m | 5.02% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 2.19m | 5.01% |
Polar Capital LLPas of 31 Dec 2023 | 2.06m | 4.70% |
D. E. Shaw & Co. LPas of 31 Dec 2023 | 1.32m | 3.02% |
Caligan Partners LPas of 31 Dec 2023 | 1.05m | 2.40% |
Acadian Asset Management LLCas of 31 Dec 2023 | 802.38k | 1.83% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 761.53k | 1.74% |
Geode Capital Management LLCas of 31 Dec 2023 | 738.55k | 1.69% |